Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa for HCV Post-Exposure Prophylaxis in Healthcare Workers
NCT03313414Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of velpatasvir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Planned start Aug 2019; status: withdrawn.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03313414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313414.